Exchange: NYSE·Updated 05:17 PM EDT
News
all
press releases
Here's Why Solventum (SOLV) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Zacks
More News
Solventum Stock Up as Q2 Earnings & Revenues Beat Estimates
SOLV's Q2 earnings and revenues beat estimates as organic sales increase 9.5%, prompting higher 2026 guidance despite ERP timing benefits.
Zacks
Solventum (SOLV) Q2 Earnings and Revenues Top Estimates
Solventum (SOLV) delivered earnings and revenue surprises of +33.51% and +2.03%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?
Zacks
Solventum (SOLV) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
The headline numbers for Solventum (SOLV) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Zacks
Solventum Corporation Bottom Line Rises In Q2
(RTTNews) - Solventum Corporation (SOLV) announced a profit for its second quarter that Increases, from the same period last year...
Nasdaq News: Markets
Solventum Reports Second Quarter 2026 Financial Results
Solventum Reports Second Quarter 2026 Financial Results Solventum Reports Second Quarter 2026 Financial Results PR Newswire EAGAN, Minn., Aug. 5, 2026 Reported sales increased 2.2%; organic sales increased 9.5%Announces intent to separate its Health Information Systems business segmentIncreases...
PR Newswire
Solventum Announces Intent to Separate its Health Information Systems Business
Solventum Announces Intent to Separate its Health Information Systems Business Solventum Announces Intent to Separate its Health Information Systems Business PR Newswire EAGAN, Minn., Aug. 5, 2026 Strengthens the focus of Solventum as a dedicated MedTech company and advances its three-phase...
PR Newswire
What's in Store for These 4 Healthcare Companies This Earnings Season?
McKesson, Cencora, Solventum and PacBio head into earnings with resilient demand offset by tariffs, funding pressure and pricing challenges.
Zacks
Solventum to Report Q2 Earnings: What's in Store for the Stock?
SOLV's Q2 results are likely to benefit from segment strength, Acera gains and cost savings, offset by tariffs and ERP-related sales timing shifts.
Zacks
Why Solventum (SOLV) is a Top Stock for the Long-Term
Finding strong, market-beating stocks with a positive earnings outlook becomes easier with the Focus List, a top feature of the Zacks Premium portfolio service.
Zacks

Advertisement|Remove ads.